# TenSixteen Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tensixteen-bio

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.tensixteen.bio
- Total disclosed funding: $30M
- Latest round: Series A (Jan 27, 2022)
- Investors on record: 2

## About

Based in California, US, and founded in 2020, TenSixteen Bio, Inc. operates as a biotechnology company focused on developing novel therapeutics for a variety of diseases using somatic mosaicism and clonal hematopoiesis (CHIP) technique. The company was co-founded by CEO Mark Chao, physician-scientist and former co-founder of Forty Seven, an immuno-oncology company, and Pradeep Natarajan. In January 2022, TenSixteen Bio, Inc. raised USD 30 million in Series A funding co-led by new investors Foresite Capital and GV. The Series A funding values TenSixteen Bio, Inc at 66.1 million post-money. 

TenSixteen Bio is building a comprehensive multi-omics and clinical data platform on CHIP (clonal hematopoiesis of indeterminate potential) coupled with a proprietary diagnostic assay on CHIP, the platform will enable the company to discover therapeutic targets of CHIP, identify which patients are at the highest risk, and bring tailored therapies to these patients in the form of a biomarker. 

The company plans to use the funding for leveraging CHIP testing and create new therapeutics that may help treat disease.

## Funding rounds

- Series A, Jan 27, 2022, $30M — GV, Foresite Capital

## Investors

- GV (https://capitalatlas.ai/funds/gv) — Series A
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series A